Form D · Biotechnology
Ovelle Bio Corp.
Dover, DE · CIK 0002139798
Offering snapshot reported Jun 10, 2026 · SEC filing
- Reported sold
- $7M Offering amount: $9.2M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 2, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 10, 2026 | Initial | $7,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-586854
Source: Form D, filed Jun 10, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Merrick Pierson Smela | Executive |
| Travis Carleton Potter | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
850 New Burton Road Suite 201
Dover, DE, 19904
Dover, DE, 19904